Fournier's gangrene in patients with type 2 diabetes using second‐line antidiabetic medications
Natalia Petruski‐Ivleva(AVEO Oncology (United States)), Saira Jan(Rutgers, The State University of New Jersey), Sebastian Schneeweiß(Brigham and Women's Hospital), Aditya Rajan(AstraZeneca (United States)), Sara Eapen(Aetion (United States))
Cited by 7
Related Papers
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study
|European Journal of Clinical Pharmacology|2002|274
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
|Annals of Internal Medicine|2019|215
Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
|Alimentary Pharmacology & Therapeutics|2009|214
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
|Annals of the Rheumatic Diseases|2023|95